-
<![CDATA[Combination Targeted Therapy Shows Comparable Infection Risk to Standard Treatment in PsA]]>
19 Sep 2025 01:42 GMT
… to those receiving standard treatment, according to findings published … 3 consecutive months of medication fill data for any … their findings to other drug combinations. Nonetheless, they … et al. Guselkumab plus golimumab combination therapy versus guselkumab …
-
Adding Golimumab to Treatment Regimen Reduced Rescue Corticosteroid Use in People With Early PsA
11 Sep 2025 00:07 GMT
… of Rheumatic and Musculoskeletal Medicine, University of Leeds, … disease-modifying antirheumatic drugs or systemic treatments. The study … linear regression. The trial design was put together … Effect of a treatment strategy utilising golimumab, methotrexate and …
-
The Effects of Disease-Modifying Antirheumatic Drugs on Cardiovascular Risk in Inflammatory Joint Diseases: Current Evidence and Uncertainties
04 Aug 2025 05:52 GMT
… large-scale clinical trials with definitive cardiovascular … treatment strategies. Preventive measures, including lifestyle changes, statins … The effects of golimumab on subclinical atherosclerosis … 47;/www.fda.gov/drugs/drug-safety-and-availability …
-
Relative Importance of Disease-Modifying Antirheumatic Drug Attributes for Patients with Rheumatoid Arthritis
04 Aug 2025 05:53 GMT
… intravenous tocilizumab, intravenous golimumab, and oral upadacitinib. … clinical trials of DMARDs gathered from the Drugs@FDA.26 … for initiating treatment, favoring taking medication over opting … for a randomised controlled trial in rheumatoid arthritis: …
-
Bio-Thera Announces Acceptance of BLA for BAT2506 Referencing Johnson & Johnson’s SIMPONI® (Golimumab)
30 Jul 2025 17:50 GMT
… Drug Administration (“FDA”) had accepted its Biologics License Application (“BLA”) for its golimumab … BLA seeks approval for the treatment of all indications currently approved … -Thera entered into with Intas Pharmaceuticals Ltd. (“Intas”) in February of …
-
Bio-Thera Submits aBLA for Simponi® (golimumab) Biosimilar BAT2506
24 Jul 2025 23:31 GMT
… Johnson & Johnson’s Simponi® (golimumab). Under a license and commercialization … AVT05 (golimumab) (previously reported Alvotech and Teva Announce First FDA Acceptance of … aBLA for Simponi® / Simponi Aria® (golimumab) …
-
Bio-Thera Solutions Announces FDA Accepts Biologics License Application For BAT2506, A Proposed Biosimilar To Simponi®
16 Jul 2025 12:37 GMT
… .S. Food and Drug Administration (FDA) has accepted its … inflammatory markers. The reference medicine golimumab has been approved in … Thera).
About Intas Pharmaceuticals
Intas Pharmaceuticals is a pioneer … Being the most affordable treatment option, Intas' …
-
Golimumab Boosts Remission Rates in AxSpA
30 Jun 2025 04:34 GMT
… remission in a tight control treatment with golimumab, regardless of gut inflammation … anti-inflammatory drugs (NSAIDs) for 4 weeks and 50 mg golimumab every … sustained remission.
IN PRACTICE:
“Our trial demonstrated that sustained inactive disease …
-
Drug-Induced Uveitis: Patterns, Pathogenesis and Clinical Implications
24 Jun 2025 14:26 GMT
… treatment.
Intravitreal Medications
Intravitreal medications are used for a variety of ocular indications. Drug … biologic immunomodulatory medications. FDA approved TNF inhibitors include infliximab, adalimumab, etanercept, golimumab, and …
-
Impact of Adherence to Golimumab on Disease Flares in Rheumatoid Arthritis: Results from a Canadian Observational Study
25 Jun 2025 20:02 GMT
… decided to initiate golimumab treatment prior to and … , csDMARDs and glucocorticoid medication, respectively (Table 1 … associated with adherence to pharmaceutical treatment for rheumatoid arthritis … 47;www.accessdata.fda.gov/drugsatfda_docs/label …